BIO.DE Biotest AG XETRA 15 Jan 2026: Oversold bounce from €42.20, watch €43.50
BIO.DE stock is staging an intraday oversold bounce after sliding to €42.20 on XETRA. The share is down -0.94% today with volume 175.00 versus an average of 129.00. Traders should watch the immediate resistance at the intraday high €43.00 and the short-term pivot near the 50-day average €42.54. This intraday move offers a defined risk-reward entry for a quick mean-reversion trade while fundamentals and sector context remain mixed.
BIO.DE stock: Intraday price action and setup
The main fact is price tested the session low at €42.20 and bounced to €43.00. The stock opened at €42.20 and last trade shows €42.20, down from a previous close of €42.60. Relative volume is 1.36, so trading is slightly above normal and supports a short-term bounce trade idea. For intraday traders, a move above €43.50 would invalidate the immediate oversold bounce thesis and signal further upside.
BIO.DE stock: Technical levels, averages and indicators
The 50-day average sits at €42.54 and the 200-day average at €41.71. Price is near both moving averages, creating a tight range for a bounce. RSI and MACD data are limited on intraday feeds, but the one-day decline of -0.94% after a year high of €43.20 suggests short-term oversold conditions. Trade plan: buy strength above €42.80 with stop below €42.00, target €43.50 then €44.50.
BIO.DE stock: Fundamentals and valuation snapshot
Biotest AG shows EPS -0.63 and PE -66.98, reflecting a negative earnings picture. Price to sales is 2.92 and price to book is 3.22. Current ratio is 4.93, and debt to equity is 1.31, indicating a strong liquidity buffer but meaningful leverage. Recent growth data show revenue growth 6.08% for FY 2024, while net income fell 79.21%, a factor weighing on medium-term valuation.
BIO.DE stock: Meyka AI grade and forecast
Meyka AI rates BIO.DE with a score out of 100: 67.01 / 100 (Grade B, HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst signals. Meyka AI’s forecast model projects €42.05 for the next year. Compared with the current price €42.20, the model implies a -0.34% downside. Forecasts are model-based projections and not guarantees.
BIO.DE stock: Catalysts, risks and sector context
Near-term catalysts include sector peer updates and XETRA listings that shift investor flows. Recent benchmarking articles reference Biotest among peers on Investing.com and XETRA stock lists on MarketBeat. Key risks are weak earnings, long inventory days 500.13, and negative operating cash flow per share -1.13. The healthcare sector on Germany exchanges is steady, which can support a measured rebound.
BIO.DE stock: Intraday oversold bounce trade plan
This strategy aims for a quick mean reversion. Entry: €42.60–€42.80 on improving bid. Stop: €41.90 to limit risk below short-term support. Targets: €43.50 (first) and €44.50 (stretch). Position size should respect capital limits and the stock’s liquidity profile with average volume 129.00 shares.
Final Thoughts
Short-term traders can treat BIO.DE stock as a defined oversold bounce candidate on XETRA after the intraday low €42.20. The bounce is supported by a tight range between the 50-day average €42.54 and the 200-day average €41.71. Meyka AI’s model projects €42.05, implying a -0.34% gap versus the current price €42.20, so the forecast is effectively neutral for a one-year horizon. We rate this trade as tactical, not structural. Use strict stops and defined targets: initial resistance €43.50 and secondary target €44.50. Monitor upcoming sector moves and peer updates on Investing.com and MarketBeat. For live quotes and order ideas see the BIO.DE page on Meyka AI for real-time signals and data. Forecasts are model-based projections and not guarantees.
FAQs
Is BIO.DE stock a buy on this intraday bounce?
BIO.DE stock can be a tactical buy for short-term traders who use tight stops. Risk control is critical because fundamentals show negative EPS -0.63 and leverage 1.31. This is not a long-term recommendation.
What price target should traders watch for BIO.DE stock?
Watch €43.50 as the first resistance and €44.50 as a stretch target. Meyka AI’s one-year forecast is €42.05, so treat intraday targets as short-term, execution-focused levels.
How does Biotest’s valuation affect the trading setup for BIO.DE stock?
Valuation metrics are mixed: price to sales 2.92 and price to book 3.22. Negative PE reflects losses. These fundamentals increase downside risk beyond intraday trades, so limit exposure accordingly.
Where can I find more real-time data on BIO.DE stock?
Use XETRA feeds, sector reports on MarketBeat, peer comparisons on Investing.com, and the BIO.DE stock page on Meyka AI for live indicators and alerts.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
